Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk

The trial explored whether Repatha®(evolocumab) reduces the risk of heart-related events in patients with heart disease.

Repatha® (evolocumab) increases the 'good cholesterol' in the blood by stopping the liver removing it and also lowers 'bad cholesterol'.

Prof Mark Caulfield describes the development of this drug and prospects for its future use on the day that successful trial results were reported by the manufacturer, Amgen.

Dr David Collier explains how the new drug works.


Download the Study Summary
(Click picture below)

Read the stories of FOURIER study patients
(Click pictures below to download)

Watch the video stories of FOURIER study patients
(Click picture below to go to our Vimeo showcase in a new page)

TRIALSCONNECT has worked alongside

This website makes use of cookies. Please see our privacy policy for details.